cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Organovo Holdings Inc
14 own
18 watching
Current Price
$1.25
$0.08
(6.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
14.81M
52-Week High
52-Week High
3.4
52-Week Low
52-Week Low
1.0
Average Volume
Average Volume
0.75M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
35.1196
iconMarket Capitalization14.81M
icon52-Week High3.4
icon52-Week Low1.0
iconAverage Volume0.75M
iconDividend Yield--
iconP/E Ratio35.1196
What does the Organovo Holdings Inc do?
Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. It is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair, and functional tissue patches for the repair or replacement of damaged tissues and organs. The company has collaboration agreements with L'Oreal USA and Merck & Co. Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More
How much money does Organovo Holdings Inc make?
News & Events about Organovo Holdings Inc.
Globe Newswire
8 months ago
Lead Molecule Poised for Phase 2 in IBDSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that ...
Zolmax
8 months ago
Organovo Holdings, Inc. (NASDAQ:ONVO Get Rating) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 291,600 shares, a decline of 11.1% from the February 13th total of 327,900 shares. Based on an average daily volume of 111,700 ...
Globe Newswire
1 year ago
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the ...
Zolmax
1 year ago
Renaissance Technologies LLC trimmed its position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO Get Rating) by 21.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,887 shares of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Organovo Holdings Inc share price today?
plus_minus_icon
Can Indians buy Organovo Holdings Inc shares?
plus_minus_icon
How can I buy Organovo Holdings Inc shares from India?
plus_minus_icon
Can Fractional shares of Organovo Holdings Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Organovo Holdings Inc stocks?
plus_minus_icon
What is today’s traded volume of Organovo Holdings Inc?
plus_minus_icon
What is today’s market capitalisation of Organovo Holdings Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Organovo Holdings Inc?
plus_minus_icon
What percentage is Organovo Holdings Inc down from its 52-Week High?
plus_minus_icon
What percentage is Organovo Holdings Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.25
$0.08
(6.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$7.57
$0.36 (4.99 %)
AxoGen, Inc.
AxoGen, Inc.
$6.90
$0.35 (5.34 %)
CEL-SCI Corp
CEL-SCI Corp
$2.06
$-0.19 (-8.44 %)
Fate Therapeutics Inc
Fate Therapeutics Inc
$2.65
$0.16 (6.43 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$7.57
$0.36 (4.99 %)
AxoGen, Inc.
AxoGen, Inc.
$6.90
$0.35 (5.34 %)
CEL-SCI Corp
CEL-SCI Corp
$2.06
$-0.19 (-8.44 %)
Fate Therapeutics Inc
Fate Therapeutics Inc
$2.65
$0.16 (6.43 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00